Ulrik M. Overgaard

Copenhagen, 7631, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Identification of the Novel HLA Allele HLA-DQA1*03:90 by Next-Generation Sequencing.

Identification of the Novel HLA Allele HLA-DQA1*03:90 by Next-Generation Sequencing.

Journal: HLA

Published: January 22, 2026

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Journal: Blood

Published: December 05, 2025

Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.

Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.

Journal: Leukemia

Published: October 03, 2025

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Journal: Blood

Published: July 28, 2025

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

Journal: Blood

Published: July 28, 2025

Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland.

Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland.

Journal: EJHaem

Published: July 08, 2025

Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.

Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.

Journal: Leukemia

Published: May 15, 2025

Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients.

Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients.

Journal: Targeted oncology

Published: April 23, 2025

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Journal: Blood

Published: April 18, 2025

Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.

Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.

Journal: British journal of haematology

Published: February 06, 2025

The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries.

The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries.

Journal: Annals of hematology

Published: January 15, 2025

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 18, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026